Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel fuller ...